Related Experiment Video
Updated: Jun 6, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Non-alcoholic fatty liver disease proteomics.
Eva Rodríguez-Suárez1, Antonio M Duce, Juan Caballería
1Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed, Technology Park of Bizkaia, Derio, Bizkaia, Spain.
Proteomics. Clinical Applications
|December 8, 2010
Summary
Researchers identified two protein markers, carbamoyl phosphate synthase 1 and 78 kDa glucose-regulated protein, that are differentially expressed in non-alcoholic steatohepatitis (NASH). This proteomic study offers new insights into NAFLD biomarkers.
Area of Science:
- Proteomics
- Hepatology
- Biomarker Discovery
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a significant cause of chronic liver injury.
- Identifying reliable biomarkers for NAFLD progression is crucial for clinical management.
Purpose of the Study:
- To investigate differential protein expression between NAFLD patients and healthy controls.
- To identify potential protein biomarkers for non-alcoholic steatohepatitis (NASH).
Main Methods:
- Proteomic analysis using Difference Gel Electrophoresis (DIGE) coupled with MALDI TOF/TOF.
- Validation of differentially expressed proteins via Western blot in tissue and serum samples.
Main Results:
- Forty-three proteins showed significant expression changes between groups.
- Two candidate markers, carbamoyl phosphate synthase 1 and 78 kDa glucose-regulated protein, were identified in NASH patients compared to controls.
Conclusions:
- Proteomics approaches combining DIGE, MALDI TOF/TOF, and Western blot are effective for identifying NAFLD biomarkers.
- Carbamoyl phosphate synthase 1 and 78 kDa glucose-regulated protein show potential as diagnostic markers for NASH.
